(S019) Radiation-Induced Liver Disease Following Liver SBRT for Primary Hepatic Malignancies: Analysis of a Prospective Institutional Study 

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Primary hepatic malignancies that are not amenable to surgical resection portend a poor prognosis, despite available treatment options. Though RILD is rare following SBRT, this study demonstrates a risk, despite close adherence to standard dose and volume constraints. Further analysis of this prospective study will seek to elicit patient parameters that may increase susceptibility to toxicities, such as RILD.

Ashley Weiner, MD, PhD, Jeffrey Olsen, MD, Daniel Ma, MD, Pawel Dyk, MD, Todd Dewees, PhD, Parag Parikh, MD; Washington University; Mayo Clinic

PURPOSE AND OBJECTIVES: Although primary liver tumors are commonly treated by surgery, transplant, radiofrequency ablation, or transarterial therapies, there is an increasing patient population that is not suited to these treatments. Stereotactic body radiotherapy (SBRT) allows precise delivery of hypofractionated radiation-a strategy that is thought to minimize the risk of radiation-induced liver disease (RILD) over conventionally fractionated radiation. The objective of this study was to evaluate the feasibility, safety, and efficacy of SBRT in the treatment of inoperable hepatocellular cancer (HCC) and intrahepatic cholangiocarcinoma (IHC).

MATERIALS AND METHODS: A total of 28 patients with inoperable HCC or IHC and Child-Pugh score ≤ 8 were enrolled on a single-institution prospective protocol. A total of 32 lesions in 26 patients were treated with a planned dose of 55 Gy in five fractions, which was reduced to maintain the mean liver dose < 20 Gy or spare 700 cc of liver with doses < 20 Gy. Treatment was delivered via linear accelerator with immobilization, daily imaging, and end-expiratory gating on fiducial markers. Kaplan-Meier survival analysis was performed. Toxicities were graded by Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) criteria, and radiographic response to treatment was scored by European Association for the Study of the Liver (EASL) guidelines.

RESULTS: The study cohort included 12 patients with HCC, 13 patients with IHC, and 1 patient with a biphenotypic tumor. Median prescribed dose was 55 Gy (range: 40–55 Gy) in five fractions. Mean tumor diameter was 5.3 cm (range: 1.6–12.3 cm), and mean PTV volume was 342 cc (range: 54–964 cc). Median follow-up was 7.7 months with a median overall survival (OS) of 9.8 months. The 6- and 12-month OS rates were 80% and 44%, respectively. On imaging 8 weeks posttreatment, complete radiographic response was noted in four patients, while six patients had a partial treatment response. Two grade 5 toxicities occurred during study follow-up. One patient with cirrhosis and a renal transplant history who was being treated with tacrolimus, a potentially hepatotoxic medication, developed RILD, which progressed to hepatic failure and death. Another patient with longstanding cirrhosis succumbed to a gastrointestinal bleed in the setting of RILD.

CONCLUSIONS: Primary hepatic malignancies that are not amenable to surgical resection portend a poor prognosis, despite available treatment options. Though RILD is rare following SBRT, this study demonstrates a risk, despite close adherence to standard dose and volume constraints. Further analysis of this prospective study will seek to elicit patient parameters that may increase susceptibility to toxicities, such as RILD.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content